Biophan expands intellectual property

Biophan Technologies (West Henrietta, New York), a developer of next-generation medical technology, reported further expansion of its intellectual property portfolio in recent weeks with 13 new applications filed — resulting in 10% growth — to a total of 140 U.S. issued or pending patents, plus international patents.

The new applications cover manufacturing the high-voltage leads used with implantable cardioverter defibrillators, when used in an MRI environment; various nanomagnetic materials, design details of conductive leads and the use of nanomagnetic material to shield them from MRI-related energy; and patent applications licensed recently from Aachen Resonance for the visualization of stents.

Texas legislation allows for care of diabetic students

The American Diabetes Association (ADA; Alexandria, Virginia) applauded the signing of the "Diabetes School Care Act," legislation in the state of Texas that is designed to help ensure that public schools in the state are responsive to the medical and educational needs of students with diabetes.

The ADA, including volunteers throughout Texas, was a primary backer of the bipartisan legislation, which will allow school personnel to be trained in diabetes care appropriate for the student and allow students with diabetes to self-manage their disease on school property.

Diabetes management is accomplished with blood glucose monitoring, administration of insulin and other medications, as well as proper nutrition and exercise, the ADA said, noting that many children are able to handle their own daily care, while others may need adult assistance.

Bio-Nano Sensium, Nanotech in beta test program

Bio-Nano Sensium Technologies (Abingdon, UK), a subsidiary of Advance Nanotech (New York), reported a limited beta test program of its wireless biosensor system. Beta-stage versions of Bio-Nano Sensium (BNS) system will be available to potential partners and customers for evaluation. Wireless biosensors are increasingly seen as a desirable treatment for a range of chronic conditions including diabetes, cardiac conditions and asthma, the company said.

The BNS system is based on what the company said is a "low-cost, disposable integrated sensor interface chip" — the Sensium — that, due to its ultra low power and small battery size, can be implanted in or worn on the body with complete freedom of movement unlike existing bulky monitoring solutions.

The Sensium is compatible with a wide range of sensors and can be configured to detect vital signs such as ECG, blood oxygen and glucose, body temperature, and even motion and mobility. The BNS system is designed to enhance the way doctors and patients monitor a host of chronic illnesses, increasing the effectiveness of available treatments and improving the quality of life for patients, the company said.

No Comments